Semaglutide is neither a miracle nor a cosmetic trick. At obesity-treatment doses it can produce clinically important weight loss and health benefits, but maintenance commonly requires continued treatment or another durable strategy.
Tirzepatide generally produces greater average weight loss than semaglutide in obesity trials, but the correct comparison uses obesity brands and doses, not casual brand substitution.
After semaglutide is stopped, appetite suppression fades, biological pressure to regain can return, and many patients recover a substantial portion of lost weight. The outcome is variable, not inevitable in the same degree.
Reducing appetite is not a superficial side effect. Appetite regulation is a central disease mechanism in obesity. Modern incretin-based medicines also affect glucose control and several downstream complications.
Yes. Many people lose weight without semaglutide, but the amount, durability, biological difficulty, and health benefit vary. The real question is which treatment intensity matches the disease.